Mirati Therapeut Stock Price, News & Analysis

Mirati Therapeutics (NASDAQ: MRTX) reported Q3 2021 financial results, revealing a net loss of $80.1 million, or $1.55 per share, improved from a loss of $87.3 million last year. The company ended the quarter with $1.2 billion in cash. Key updates include progress on adagrasib for KRASG12C-mutated lung cancer, with FDA NDA submission expected by year-end. Positive preliminary Phase 1b results show a 100% disease control rate in patients treated with adagrasib and pembrolizumab. The pipeline includes further developments in sitravatinib and MRTX1719, with continued advancements in clinical trials.

Mirati Therapeutics, Inc. (NASDAQ: MRTX) will report its financial results for Q3 2021 on November 8 at 4:30 p.m. ET. The announcement will include corporate updates alongside financial results during a conference call. Investors can join the call via a live webcast or by phone. Mirati focuses on developing breakthrough therapies for cancer, particularly targeting KRAS mutations with investigational drugs like adagrasib (MRTX849) and sitravatinib. The company emphasizes addressing significant unmet needs in oncology.

Mirati Therapeutics (NASDAQ: MRTX) announced a clinical collaboration with Sanofi to evaluate the combination of adagrasib, a KRAS^G12C inhibitor, with Sanofi's SAR442720 (RMC-4630), an SHP2 inhibitor. This Phase 1/2 study will focus on patients with previously-treated non-small cell lung cancer (NSCLC) harboring KRAS^G12C mutations. The collaboration aims to optimize clinical outcomes and shares study costs. Mirati is advancing a robust development program for adagrasib, targeting high unmet needs in oncology.

Mirati Therapeutics (NASDAQ: MRTX) announced new clinical and preclinical research to be presented at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics from October 7-10, 2021. Key presentations include:

• MRTX1719: First-in-class PRMT5 inhibitor for MTAP-deleted cancers.
• MRTX1133: KRAS^G12D inhibitor with promising preclinical data.
• Adagrasib: Data from KRYSTAL-1 trial on KRAS^G12C-mutated pancreatic cancer.

Mirati focuses on innovative therapies targeting genetic and immunological cancer drivers.

Mirati Therapeutics, Inc. (NASDAQ: MRTX) announced an inducement stock option grant to newly appointed CEO David Meek, allowing him to purchase 150,300 shares at an exercise price of $167.10. The stock options will vest over four years, with the first 25% vesting after one year. This grant is compliant with NASDAQ Listing Rule 5635(c)(4) and aims to align Mr. Meek's interests with that of the shareholders. Mirati is focused on developing therapies for cancer, particularly targeting KRAS mutations and receptor tyrosine kinases.

Mirati Therapeutics (MRTX) has appointed David Meek as its new Chief Executive Officer (CEO) effective immediately. He joins the Board of Directors, succeeding Charles M. Baum, who remains as President and head of R&D. Mr. Meek brings over 30 years of industry experience, notably leading Ipsen as CEO. Under his leadership, Mirati aims to advance its oncology pipeline, including the adagrasib and sitravatinib therapies with IND submissions anticipated in Q4 2021. The leadership transition is expected to build upon Mirati's commitment to targeted cancer therapies.

Mirati Therapeutics (NASDAQ: MRTX) reported positive topline results from the Phase 2 KRYSTAL-1 study for adagrasib, targeting advanced non-small cell lung cancer (NSCLC) with the KRAS^G12C mutation. The study showed an objective response rate (ORR) of 43% and a disease control rate of 80% among patients with a median follow-up of 9 months. With plans for a New Drug Application submission by Q4 2021, the findings bolster confidence in adagrasib as a promising therapy. Additionally, updated Phase 1 findings revealed an ORR of 58% in a smaller cohort.

Mirati Therapeutics (NASDAQ: MRTX) announced positive results from the Phase 1/2 KRYSTAL-1 study of adagrasib in patients with KRAS^G12C-mutated colorectal cancer. The monotherapy arm showed a response rate of 22% and a disease control rate of 87%. In combination with cetuximab, the response rate rose to 43%, with 100% disease control in evaluable patients. The study demonstrated a manageable safety profile with no Grade 5 treatment-related adverse events. These findings will support further evaluation in ongoing studies, including a Phase 3 trial.